Pill Identifier App

Ludiomil

Generic Name: maprotiline hydrochloride
Dosage Form: Tablets USP

Ludiomil®

C96-65 (Rev. 11/96)

666536

Ludiomil® 

maprotiline hydrochloride tablets USP

Prescribing Information

Ludiomil Description

Ludiomil, maprotiline hydrochloride USP, is a tetracyclic antidepressant, available as 25-mg, 50-mg and 75-mg tablets for oral administration. Its chemical name is N-methyl-9,10-ethanoanthracene-9 (10H)-propylamine hydrochloride, and its structural formula is

Slideshow: 10 Common Symptoms That Should Never Be Ignored

      Maprotiline hydrochloride USP is a fine, white to off-white, practically odorless crystalline powder. It is freely soluble in methanol and in chloroform, slightly soluble in water, and practically insoluble in isooctane. Its molecular weight is 313.87.

      Inactive Ingredients. Calcium phosphate, cellulose compounds, colloidal silicon dioxide, FD&C Yellow No. 6 Aluminum Lake (25-mg and 50-mg tablets), lactose, magnesium stearate, stearic acid, talc, titanium dioxide, polyethylene glycol, polysorbate, crospovidone, and iron oxide (75-mg tablets).

Ludiomil - Clinical Pharmacology

The mechanism of action of Ludiomil is not precisely known. It does not act primarily by stimulation of the central nervous system and is not a monoamine oxidase inhibitor. The postulated mechanism of Ludiomil is that it acts primarily by potentiation of central adrenergic synapses by blocking reuptake of norepinephrine at nerve endings. This pharmacologic action is thought to be responsible for the drug's antidepressant and anxiolytic effects.

      The mean time to peak is 12 hours. The half-life of elimination averages 51 hours.

      Steady-state levels measured prior to the morning dose on a one-dosage regimen are summarized as follows:

Regimen Average Minimum

Concentration

ng/ml
95% Confidence

Limits

ng/mL
50 mg x 3 daily 238 181—295

Indications and Usage for Ludiomil

Ludiomil is indicated for the treatment of depressive illness in patients with depressive neurosis (dysthymic disorder) and manic-depressive illness, depressed type (major depressive disorder). Ludiomil is also effective for the relief of anxiety associated with depression.

CONTRAINDICATIONS

Ludiomil is contraindicated in patients hypersensitive to Ludiomil and in patients with known or suspected seizure disorders. It should not be given concomitantly with monoamine oxidase (MAO) inhibitors. A minimum of 14 days should be allowed to elapse after discontinuation of MAO inhibitors before treatment with Ludiomil is initiated. Effects should be monitored with gradual increase in dosage until optimum response is achieved. The drug is not recommended for use during the acute phase of myocardial infarction.

Warnings

Seizures have been associated with the use of Ludiomil.

      Most of the seizures have occurred in patients without a known history of seizures. However, in some of these cases, other confounding factors were present, including concomitant medications known to lower the seizure threshold, rapid escalation of the dosage of Ludiomil, and dosage that exceeded the recommended therapeutic range. The incidence of direct reports is less than 1/10 of 1%. The risk of seizures may be increased when Ludiomil is taken concomitantly with phenothiazines, when the dosage of benzodiazepines is rapidly tapered in patients receiving Ludiomil or when the recommended dosage of Ludiomil is exceeded. While a cause-and-effect relationship has not been established, the risk of seizures in patients treated with Ludiomil may be reduced by (1) initiating therapy at a low dosage, (2) maintaining the initial dosage for 2 weeks before raising it gradually in small increments as necessitated by the long half-life of Ludiomil (average 51 hours), and (3) keeping the dosage at the minimally effective level during maintenance therapy. (See DOSAGE AND ADMINISTRATION.)

Extreme caution should be used when this drug is given to:

  • patients with a history of myocardial infarction;
  • patients with a history or presence of cardiovascular disease because of the possibility of conduction defects, arrhythmias, myocardial infarction, strokes and tachycardia.

Precautions

General

The possibility of suicide in seriously depressed patients is inherent in their illness and may persist until significant remission occurs. Therefore, patients must be carefully supervised during all phases of treatment with Ludiomil, and prescriptions should be written for the smallest number of tablets consistent with good patient management.

      Hypomanic or manic episodes have been known to occur in some patients taking tricyclic antidepressant drugs, particularly in patients with cyclic disorders. Such occurrences have also been noted, rarely, with Ludiomil.

      Prior to elective surgery, Ludiomil should be discontinued for as long as clinically feasible, since little is known about the interaction between Ludiomil and general anesthetics.

      Ludiomil should be administered with caution in patients with increased intraocular pressure, history of urinary retention, or history of narrow-angle glaucoma because of the drug's anticholinergic properties.

Information for Patients

Patients should be warned of the association between seizures and the use of Ludiomil. Moreover, they should be informed that this association is enhanced in patients with a known history of seizures and in those patients who are taking certain other drugs. (See WARNINGS.)

      Warn patients to exercise caution about potentially hazardous tasks, or operating automobiles or machinery since the drug may impair mental and/or physical abilities.

      Ludiomil may enhance the response to alcohol, barbiturates, and other CNS depressants, requiring appropriate caution of administration.

Laboratory Tests

Ludiomil should be discontinued if there is evidence of pathological neutrophil depression. Leukocyte and differential counts should be performed in patients who develop fever and sore throat during therapy.

Drug Interactions

Close supervision and careful adjustment of dosage are required when administering Ludiomil concomitantly with anticholinergic or sympathomimetic drugs because of the possibility of additive atropine-like effects.

      Concurrent administration of Ludiomil with electroshock therapy should be avoided because of the lack of experience in this area.

      Caution should be exercised when administering Ludiomil to hyperthyroid patients or those on thyroid medication because of the possibility of enhanced potential for cardiovascular toxicity of Ludiomil.

      Ludiomil should be used with caution in patients receiving guanethidine or similar agents since it may block the pharmacologic effects of these drugs.

      The risk of seizures may be increased when Ludiomil is taken concomitantly with phenothiazines or when the dosage of benzodiazepines is rapidly tapered in patients receiving Ludiomil.

      Because of the pharmacologic similarity of Ludiomil to the tricyclic antidepressants, the plasma concentration of Ludiomil may be increased when the drug is given concomitantly with hepatic enzyme inhibitors (e.g., cimetidine, fluoxetine) and decreased by concomitant administration with hepatic enzyme inducers (e.g., barbiturates, phenytoin), as has occurred with tricyclic antidepressants. Adjustment of the dosage of Ludiomil may therefore be necessary in such cases.

      (See PRECAUTIONS, Information for Patients.)

Carcinogenesis, Mutagenesis, Impairment of Fertility

Carcinogenicity and chronic toxicity studies have been conducted in laboratory rats and dogs. No drug- or dose-related occurrence of carcinogenesis was evident in rats receiving daily oral doses up to 60 mg/kg of Ludiomil for eighteen months or in dogs receiving daily oral doses up to 30 mg/kg of Ludiomil for one year. In addition, no evidence of mutagenic activity was found in offspring of female mice mated with males treated with up to 60 times the maximum daily human dose.

Pregnancy Category B

Reproduction studies have been performed in female laboratory rabbits, mice, and rats at doses up to 1.3, 7, and 9 times the maximum daily human dose respectively and have revealed no evidence of impaired fertility or harm to the fetus due to Ludiomil. There are, however, no adequate and well-controlled studies in pregnant women. Because animal reproduction studies are not always predictive of human response, this drug should be used during pregnancy only if clearly needed.

Labor and Delivery

Although the effect of Ludiomil on labor and delivery is unknown, caution should be exercised as with any drug with CNS depressant action.

Nursing Mothers

Ludiomil is excreted in breast milk. At steady state, the concentrations in milk correspond closely to the concentrations in whole blood. Caution should be exercised when Ludiomil is administered to a nursing woman.

Pediatric Use

Safety and effectiveness in pediatric patients below the age of 18 have not been established.

Adverse Reactions

The following adverse reactions have been noted with Ludiomil and are generally similar to those observed with tricyclic antidepressants.

Cardiovascular

Rare occurrences of hypotension, hypertension, tachycardia, palpitation, arrhythmia, heart block, and syncope have been reported with Ludiomil.

Psychiatric

Nervousness (6%), anxiety (3%), insomnia (2%), and agitation (2%); rarely, confusional states (especially in the elderly), hallucinations, disorientation, delusions, restlessness, nightmares, hypomania, mania, exacerbation of psychosis, decrease in memory, and feelings of unreality.

Neurological

Drowsiness (16%), dizziness (8%), tremor (3%), and, rarely, numbness, tingling, motor hyperactivity, akathisia, seizures, EEG alterations, tinnitus, extrapyramidal symptoms, ataxia, and dysarthria.

Anticholinergic

Dry mouth (22%), constipation (6%), and blurred vision (4%); rarely, accommodation disturbances, mydriasis, urinary retention, and delayed micturition.

Allergic

Rare instances of skin rash, petechiae, itching, photosensitization, edema, and drug fever.

Gastrointestinal

Nausea (2%) and, rarely, vomiting, epigastric distress, diarrhea, bitter taste, abdominal cramps and dysphagia.

Endocrine

Rare instances of increased or decreased libido, impotence, and elevation or depression of blood sugar levels.

Other

Weakness and fatigue (4%) and headache (4%); rarely, altered liver function, jaundice, weight loss or gain, excessive perspiration, flushing, urinary frequency, increased salivation, nasal congestion, and alopecia.

Note

Although there have been only isolated reports of the following adverse reactions with Ludiomil, its pharmacologic similarity to tricyclic antidepressants requires that each reaction be considered when administering Ludiomil.

  • Bone marrow depression, including agranulocytosis, eosinophilia, purpura, and thrombocytopenia, myocardial infarction, stroke, peripheral neuropathy, sublingual adenitis, black tongue, stomatitis, paralytic ileus, gynecomastia in the male, breast enlargement and galactorrhea in the female, and testicular swelling.

Post-Introduction Reports

Several voluntary reports of interstitial pneumonitis, which were in some cases associated with eosinophilia and increased liver enzymes, have been received since market introduction. However, there is no clear causal relationship.

Overdosage

Deaths may occur from overdosage with this class of drugs. Multiple drug ingestion (including alcohol) is common in deliberate overdose. As the management is complex and changing, it is recommended that the physician contact a poison control center for current information on treatment. Signs and symptoms of toxicity develop rapidly after overdose. Therefore, hospital monitoring is required as soon as possible.

Animal Oral LD50: The oral LD50 of Ludiomil is 600-750 mg/kg in mice, 760-900 mg/kg in rats, > 1000 mg/kg in rabbits, > 300 mg/kg in cats, and > 30 mg/kg in dogs.

Manifestations

Data dealing with overdosage in humans are limited with only a few cases on record. Signs and symptoms of Ludiomil overdose are similar to those seen with tricyclic overdose. Critical manifestations of overdose include cardiac dysrhythmias, severe hypotension, convulsions, and CNS depression including coma. Changes in the electrocardiogram, particularly in QRS axis or width, are clinically significant indicators of toxicity. Other clinical manifestations include drowsiness, tachycardia, ataxia, vomiting, cyanosis, shock, restlessness, agitation, hyperpyrexia, muscle rigidity, athetoid movements, and mydriasis. Since congestive heart failure has been seen with overdosages of tricyclic antidepressants, it should be considered with Ludiomil overdosage.

Management

Obtain an ECG and immediately initiate cardiac monitoring. Protect the patient's airway, establish an intravenous line, and initiate gastric decontamination. A minimum of 6 hours of observation with cardiac monitoring and observation for signs of CNS or respiratory depression, hypotension, cardiac dysrhythmias and/or conduction blocks, and seizures is necessary. If signs of toxicity occur at any time during this period, extended monitoring is required. There are case reports of patients succumbing to fatal dysrhythmias late after tricyclic overdose; these patients had clinical evidence of significant poisoning prior to death and most received inadequate gastrointestinal decontamination. Monitoring of plasma drug levels should not guide management of the patient.

Gastrointestinal Decontamination

All patients suspected of overdose should receive gastrointestinal decontamination. This should include large volume gastric lavage followed by activated charcoal. If consciousness is impaired, the airway should be secured prior to lavage. Emesis is contraindicated.

Cardiovascular

A maximal limb-lead QRS duration of ≥ 0.10 seconds may be the best indication of the severity of the overdose. Intravenous sodium bicarbonate should be used to maintain the serum pH in the range of 7.45 to 7.55. If the pH response is inadequate, hyperventilation may also be used. Concomitant use of hyperventilation and sodium bicarbonate should be done with extreme caution, with frequent pH monitoring. A pH >7.60 or a Pco2 < 20 mmHg is undesirable. Dysrhythmias unresponsive to sodium bicarbonate therapy/hyperventilation may respond to lidocaine, bretylium, or phenytoin. Type 1A and 1C antiarrhythmics are generally contraindicated (e.g., quinidine, disopyramide, and procainamide).

      In rare instances, hemoperfusion may be beneficial in acute refractory cardiovascular instability in patients with acute toxicity. However, hemodialysis, peritoneal dialysis, exchange transfusions, and forced diuresis generally have been reported as ineffective.

CNS

In patients with CNS depression, early intubation is advised because of the potential for abrupt deterioration. Seizures should be controlled with benzodiazepines, or if these are ineffective, other anticonvulsants (e.g., phenobarbital, phenytoin). Physostigmine is not recommended except to treat life-threatening symptoms that have been unresponsive to other therapies, and then only in consultation with a poison control center.

Psychiatric Follow-up

Since overdosage is often deliberate, patients may attempt suicide by other means during the recovery phase. Psychiatric referral may be appropriate.

Pediatric Management

The principles of management of child and adult overdosages are similar. It is strongly recommended that the physician contact the local poison control center for specific pediatric treatment.

Ludiomil Dosage and Administration

A single daily dose is an alternative to divided daily doses. Therapeutic effects are sometimes seen within 3 to 7 days, although as long as 2 to 3 weeks are usually necessary.

Initial Adult Dosage

An initial dosage of 75 mg daily is suggested for outpatients with mild-to-moderate depression. However, in some patients, particularly the elderly, an initial dosage of 25 mg daily may be used. Because of the long half-life of Ludiomil, the initial dosage should be maintained for two weeks. The dosage may then be increased gradually in 25-mg increments as required and tolerated. In most outpatients a maximum dose of 150 mg daily will result in therapeutic efficacy. It is recommended that this dose not be exceeded except in the most severely depressed patients. In such patients, dosage may be gradually increased to a maximum of 225 mg.

      More severely depressed, hospitalized patients should be given an initial daily dose of 100 mg to 150 mg which may be gradually increased as required and tolerated. Most hospitalized patients with moderate-to-severe depression respond to a daily dose of 150 mg although dosages as high as 225 mg may be required in some cases. Daily dosage of 225 mg should not be exceeded.

Elderly Patients

In general, lower dosages are recommended for patients over 60 years of age. Dosages of 50 mg to 75 mg daily are usually satisfactory as maintenance therapy for elderly patients who do not tolerate higher amounts.

Maintenance

Dosage during prolonged maintenance therapy should be kept at the lowest effective level. Dosage may be reduced to levels of 75 mg to 150 mg daily during such periods, with subsequent adjustment depending on therapeutic response.

How is Ludiomil Supplied

Tablets 25 mg – oval, dark orange, scored, coated (imprinted CIBA 110)

      Bottles of 100……………………………………………………...NDC 0083-0110-30

Tablets 50 mg – round, dark orange, scored, coated (imprinted CIBA 26)

      Bottles of 100……………………………………………………...NDC 0083-0026-30

Tablets 75 mg – oval, white, scored, coated (imprinted CIBA 135)

      Bottles of 100……………………………………………………...NDC 0083-0135-30

Do not store above 86°F (30°C).

Dispense in tight container (USP).

C96-65 (Rev. 11/96)

C I B A

Ciba-Geigy Corporation

Pharmaceuticals Division

Summit, New Jersey 07901

Ludiomil 
maprotiline hydrochloride tablet
Product Information
Product Type HUMAN PRESCRIPTION DRUG LABEL Item Code (Source) NDC:0083-0110
Route of Administration ORAL DEA Schedule     
Active Ingredient/Active Moiety
Ingredient Name Basis of Strength Strength
maprotiline hydrochloride (maprotiline) maprotiline 25 mg
Inactive Ingredients
Ingredient Name Strength
Calcium phosphate  
cellulose compounds  
colloidal silicon dioxide  
crospovidone  
FD&C Yellow No. 6 Aluminum Lake  
lactose  
magnesium stearate  
polyethylene glycol  
polysorbate  
stearic acid  
talc  
titanium dioxide  
Product Characteristics
Color ORANGE (dark orange) Score 2 pieces
Shape OVAL (oval) Size 10mm
Flavor Imprint Code CIBA;110
Contains         
Coating true Symbol false
Packaging
# Item Code Package Description
1 NDC:0083-0110-30 100 TABLET (100 TABLET) in 1 BOTTLE
Ludiomil 
maprotiline hydrochloride tablet
Product Information
Product Type HUMAN PRESCRIPTION DRUG LABEL Item Code (Source) NDC:0083-0026
Route of Administration ORAL DEA Schedule     
Active Ingredient/Active Moiety
Ingredient Name Basis of Strength Strength
maprotiline hydrochloride (maprotiline) maprotiline 50 mg
Inactive Ingredients
Ingredient Name Strength
Calcium phosphate  
cellulose compounds  
colloidal silicon dioxide  
crospovidone  
FD&C Yellow No. 6 Aluminum Lake  
lactose  
magnesium stearate  
polyethylene glycol  
polysorbate  
stearic acid  
talc  
titanium dioxide  
Product Characteristics
Color ORANGE (dark orange) Score 2 pieces
Shape ROUND (round) Size 7mm
Flavor Imprint Code CIBA;26
Contains         
Coating true Symbol false
Packaging
# Item Code Package Description
1 NDC:0083-0026-30 100 TABLET (100 TABLET) in 1 BOTTLE
Ludiomil 
maprotiline hydrochloride tablet
Product Information
Product Type HUMAN PRESCRIPTION DRUG LABEL Item Code (Source) NDC:0083-0135
Route of Administration ORAL DEA Schedule     
Active Ingredient/Active Moiety
Ingredient Name Basis of Strength Strength
maprotiline hydrochloride (maprotiline) maprotiline 75 mg
Inactive Ingredients
Ingredient Name Strength
Calcium phosphate  
cellulose compounds  
colloidal silicon dioxide  
crospovidone  
iron oxide  
lactose  
magnesium stearate  
polyethylene glycol  
polysorbate  
stearic acid  
talc  
titanium dioxide  
Product Characteristics
Color WHITE (white) Score 2 pieces
Shape OVAL (oval) Size 11mm
Flavor Imprint Code CIBA;135
Contains         
Coating true Symbol false
Packaging
# Item Code Package Description
1 NDC:0083-0135-30 100 TABLET (100 TABLET) in 1 BOTTLE
Labeler - Ciba-Geigy Corporation
Revised: 02/2006
 
Ciba-Geigy Corporation
Hide
(web2)